美国斯克利普斯研究所2024年招聘博士后（疫苗开发）

斯克利普斯研究所（Scripps Research，旧称The Scripps Research Institute，缩写为TSRI）是一所私立的非营利性的生物医学研究机构，成立于1924年。斯克里普斯研究学院是美国同类机构中最大的。斯克里普斯研究所基础研究含盖免疫学，分子和细胞生物学，化学，神经科学，自身免疫性疾病，心血管病学，病毒学和合成疫苗的发展。TSRI在这些学科领域的研究均获得国际上的公认，其中以在生物分子的基本机构和设计方式的研究方面表现尤为突出，是少数几个世界领先的中心之一。根据美国新闻与世界报道在2007年进行的排名，斯克里普斯研究学院在美国最好的生物科学研究院中排名第7位，在最好的化学研究院中排名第6位。

Postdoctoral Associate – Zhu Lab

Employer

Scripps Research

Location

La Jolla, California

Salary

$70,000 to $80,000 + benefits

Closing date

Jul 29, 2024

Postdoctoral Positions Available

Postdoctoral positions are available in Dr. Jiang Zhu's laboratory for highly motivated candidates who are interested in vaccine development for viral pathogens such as HIV-1, HCV, Flu, SARS-CoV-1/2, MERS-CoV, Ebola/Marburg, RSV/hMPV, and ZIKV. Salary is in the range of $70,000 to $80,000 depending on prior experience and qualifications. Dr. Zhu holds a joint appointment in the Department of Integrative Structural and Computational Biology (ISCB) and the Department of Immunology and Microbiology at Scripps Research in La Jolla, CA (www.scripps.edu). Dr. Zhu's laboratory combines structure-based antigen design, protein nanoparticle engineering, animal immunization, single-cell technologies, and immunological assays to develop and evaluate next-generation vaccines. Multiple vaccine candidates are currently under clinical development with ongoing and planned phase-I human trials. Details of Dr. Zhu's laboratory, ongoing research projects, and recent publications can be found at www.jzhulab.org/

Dr. Zhu is also the co-founder of Uvax Bio LLC (www.uvaxbio.com), a vaccine biotechnology company that aims to address global health challenges with innovative vaccine solutions. An HIV-1 nanoparticle vaccine candidate developed by the Zhu lab is currently in the Phase 1 clinical trial in Australia (ANZCTR registration #: ACTRN12624000064505), which is sponsored by Uvax Bio. An NIH-sponsored Phase 1 clinical trial is under preparation and is expected to take place in early 2025.

Research projects will be focused on the development and validation of various microbial systems for expression of viral glycoproteins and nanoparticles, such as glycoengineered Escherichia coli, Pichia pastoris, and Saccharomyces cerevisiae. Microbially produced glycoprotein antigens will be structurally and functionally characterized to facilitate vaccine development.

Successful candidates will have a recent Ph.D. in microbiology, glycobiology, bioengineering, and other related fields. Candidates with knowledge and experience in bacterial and yeast expression, upstream and downstream processes, microbial fermentation in shake flasks and bioreactors, and subsequent harvesting and analyses are especially encouraged to apply. Plasmid construction and strain/clone generation may be required for this position. Extensive working experience in yeast systems will be a plus.

Interested applicants should send the following materials, preferably as a single PDF file, by email to Dr. Jiang Zhu (jiang@scripps.edu):

Cover letter indicating current and future research interests

Expected starting date

Curriculum vitae

Brief summary of previous research experience (2-3 pages)

Names and contact information for 3 references.